To start off the new year, NeuroSens asked some MS experts from across Canada what developments in multiple sclerosis research and management we can expect to see. Some issues were necessarily related to COVID-21. But the prognosticators also identified several important questions that may be answered in the months ahead.
To close out the pandemic year 2020, we’ve compiled a list of proposed awards for your consideration in the field of multiple sclerosis.
The International Panel on Diagnosis of Multiple Sclerosis is considering potential revisions to its 2017 McDonald criteria for the diagnosis of multiple sclerosis, but no formal changes are expected soon, according to Dr. Jeffrey Cohen at the ACTRIMS lecture presented at the 28th European Charcot Foundation meeting, November 25, 2020.
A new analysis suggests that ozanimod (Zeposia) may have a better safety profile than fingolimod despite being similar agents (Swallow et al. J Comp Eff Res 2020;9:275-285). Both drugs are sphingosine-1-phosphate (S1P) receptor agonists that act as functional antagonists, sequestering T cells in secondary lymphoid organs. Fingolimod acts on S1PR-1,3,4,5, whereas ozanimod (like siponimod) is selective to S1PR1,5. Ozanimod was approved in Canada for the treatment of relapsing MS in October 2020.